Results 231 to 240 of about 40,634 (335)

Electronic Patient File‐Embedded Model‐Informed Precision Dosing Compared with Physician Dosing of Tacrolimus in Kidney Transplantation

open access: yesClinical Pharmacology &Therapeutics, Volume 119, Issue 2, Page 381-392, February 2026.
Model‐informed precision dosing (MIPD) of tacrolimus in renal allograft recipients, evaluated in silico, demonstrated improved (time to and) probability of target concentration attainment and smaller deviations from target range. Using simulated tacrolimus concentration‐time profiles, a study of 200 patients was predicted to have sufficient power to ...
Dirk R.J. Kuypers   +6 more
wiley   +1 more source

Large Language Models for Clinical Trial Protocol Assessments

open access: yesClinical Pharmacology &Therapeutics, Volume 119, Issue 2, Page 393-402, February 2026.
The purpose was to evaluate the utility of large language models (LLMs) for reviewing the statistical analysis plan (SAP) and pharmacokinetics–pharmacodynamics (PK–PD) components of clinical trial protocols. Clinical trial protocols and SAPs were obtained from clinicaltrials.gov for a testbed of 15 small‐molecule drugs, biologics, and global antibiotic
Euibeom Shin   +2 more
wiley   +1 more source

Live-attenuated foot-and-mouth disease virus vaccine engineered by codon deoptimization induces a strong protective immune response in cattle. [PDF]

open access: yesNPJ Vaccines
Attreed SE   +15 more
europepmc   +1 more source

An Evaluation of the Drug Interaction Potential of Encorafenib in Combination With Binimetinib Using the Inje Cocktail in Patients With Cancer

open access: yesClinical Pharmacology &Therapeutics, Volume 119, Issue 2, Page 375-380, February 2026.
A clinical drug–drug interaction (DDI) study was designed to evaluate the effect of single and multiple oral doses of encorafenib on the single oral dose pharmacokinetics (PK) of the cytochrome P450 (CYP) enzyme probe substrates, losartan (CYP2C9), midazolam (CYP3A4), caffeine (CYP1A2), omeprazole (CYP2C19), and dextromethorphan (CYP2D6) administered ...
Joseph Piscitelli   +6 more
wiley   +1 more source

Ruxolitinib Suppresses Interferon‐γ‐Induced JAK/STAT Activation in Oral Keratinocytes

open access: yesClinical and Experimental Dental Research, Volume 12, Issue 1, February 2026.
ABSTRACT Objectives The Janus kinase (JAK)/Signal Transducer and Activator of Transcription (STAT) pathway plays a crucial role in oral inflammatory diseases such as oral lichen planus (OLP) and periodontitis. Interferon‐gamma (IFN‐γ) is a cytokine that activates the JAK/STAT pathway.
Kim N. Stolte   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy